掌阅科技股份有限公司 2025 年第三季度报告 证券代码：603533 证券简称：掌阅科技 掌阅科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人成湘均、主管会计工作负责人张维聪及会计机构负责人（会计主管人员）朱丹保证季 度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 一、主要财务数据 注："本报告期"指本季度初至本季度末 3 个月期间，下同。 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 同期增减变动幅 度(%) | 年初至报告期末 | 增减变动幅度 | | | | ...

2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 南京证券股份有限公司 2025 年第三季度报告 证券代码：601990 证券简称：南京证券 南京证券股份有限公司 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 项目 本报告期 上年同期 本报告期比上 年同期增减变 动幅度(%) 年初至报告期 末 上年同期 年初至报告期 末比上年同期 增减变动幅度 (%) 调整前 调整后 调整后 调整前 调整后 调整后 营业收入 684,499,699.55 690,510,847.61 555,416,270.53 23.24 2,262,095,344.56 2,368,127,25 ...

Financial Performance - The company's operating revenue for the third quarter was ¥971,372,306.12, a decrease of 4.65% compared to the same period last year[4] - The total profit for the quarter was ¥142,242,922.85, reflecting an increase of 7.55% year-over-year[4] - Net profit attributable to shareholders was ¥120,540,708.48, up by 4.15% compared to the same quarter last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥2,736,052,670.24, a 3.46% increase from ¥2,644,762,353.56 in the same period of 2024[21] - Net profit for the first three quarters of 2025 was ¥340,778,059.35, representing a 7.93% increase compared to ¥315,755,268.67 in 2024[22] - Earnings per share remained stable at ¥0.85 for both 2025 and 2024[23] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥485,340,683.74, an increase of 63.33%[5][11] - The net cash flow from operating activities increased to $485.34 million from $297.15 million, representing a growth of approximately 63.2% year-over-year[24] - Cash inflow from operating activities totaled ¥2,926,721,100.30, slightly up from ¥2,924,762,172.23 in the previous year[23] - Cash inflow from investment activities surged to $4.87 billion, up from $1.91 billion, indicating a significant increase of about 154.5%[24] - The net cash flow from investment activities was negative at -$760.94 million, compared to -$256.99 million, reflecting a decline in investment returns[24] - Cash inflow from financing activities amounted to $1.22 billion, with a net cash flow of $1.11 billion, a substantial improvement from a net outflow of -$14.10 million[24] - The total cash flow for the period was a net increase of $836.77 million, compared to $24.40 million in the prior year, reflecting a significant improvement[24] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,468,254,452.63, representing a growth of 21.15% from the end of the previous year[5] - The company's current assets totaled CNY 4.51 billion, up from CNY 2.98 billion, indicating a significant increase of approximately 51.3%[16] - Total liabilities increased to ¥1,486,185,982.21, up from ¥1,393,369,525.16, reflecting a growth of 6.67%[18] - The equity attributable to shareholders increased to ¥6,982,068,470.42, a rise of 24.75% year-over-year[5] - Total equity attributable to shareholders rose to ¥6,982,068,470.42, an increase of 24.74% from ¥5,596,777,565.36[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,821[12] - The largest shareholder, Weigao Group Co., Ltd., holds 41.11% of the shares, totaling 171,755,909 shares[13] - The company reported a total of 10,485,839 shares held in an unconfirmed account, pending certification for foreign shareholders[15] - There were no changes in the participation of major shareholders in margin financing and securities lending activities[15] Expenses and Other Income - Total operating costs increased to ¥2,345,783,937.85, up 3.05% from ¥2,276,301,286.47 year-over-year[21] - Research and development expenses decreased to ¥105,705,786.32 from ¥121,914,072.63, a reduction of 13.27%[21] - The company reported a decrease in financial expenses, with a net expense of ¥508,267.91 compared to a net income of ¥2,209,726.54 in the previous year[21] - Other income decreased significantly to ¥17,076,905.61 from ¥32,718,401.80, a decline of 47.8%[21] Inventory and Receivables - The accounts receivable stood at CNY 886.48 million, slightly down from CNY 899.70 million, showing a decrease of about 1.3%[16] - Inventory increased to CNY 819.73 million from CNY 757.07 million, marking an increase of approximately 8.3%[16] Changes in Accounting Standards - The company will not apply new accounting standards starting from 2025, as per the announcement[25]

引力传媒股份有限公司 2025 年第三季度报告 证券代码：603598 证券简称：引力传媒 引力传媒股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 √适用 □不适用 □是√否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 | | | 年初至报告期末 | | | --- | --- | --- | --- | --- | --- | --- | | | | 年同期增减变 | | 年初至报告期末 | 比上年同期增减 | | | | | 动幅度(%) | | | 变动幅度(%) | | | 营业收入 | 1,919,401,235.75 | ...

Financial Performance - The company's revenue for the third quarter reached ¥189,915,553.50, representing a year-on-year increase of 61.21%[4] - The total profit for the quarter was a loss of ¥5,944,294.57, with a net loss attributable to shareholders of ¥16,031,453.91[4] - The company reported a net cash flow from operating activities of ¥27,488,827.13 for the year-to-date period[4] - The net profit attributable to shareholders increased due to the total profit growth from the beginning of the year to the end of the reporting period[9] - Cash flow from operating activities increased due to higher sales revenue and improved collection compared to the same period last year[9] - The net profit for the first three quarters of 2025 was ¥16.1 million, a turnaround from a net loss of ¥61.7 million in the same period of 2024[30] - The operating profit for the first three quarters of 2025 was ¥28.5 million, compared to an operating loss of ¥77.3 million in 2024[30] Research and Development - Research and development expenses amounted to ¥24,027,176.88, accounting for 12.65% of total revenue, a decrease of 6.44 percentage points compared to the previous year[4] - The company plans to continue increasing investment in new drug promotion and research and development efforts[4] - Research and development expenses for the first three quarters of 2025 were ¥65.0 million, slightly up from ¥64.0 million in 2024, indicating continued investment in innovation[30] - The Phase III clinical trial for the integrase inhibitor ACC017 has officially commenced, with ethical approvals obtained from multiple hospitals, indicating strong progress in HIV treatment development[15] - The compound ADC118, a new drug for HIV treatment, has received clinical trial approval, potentially offering differentiated advantages in patient care if successfully launched[16] - The raw material for the drug Dolutegravir has been approved for market application, which will enhance supply security and reduce production costs for the company[17] - The company is advancing its research on long-acting HIV prevention drugs, with promising preliminary results indicating good antiviral activity and safety[18] - The product pipeline includes a diverse range of HIV treatments, showcasing the company's commitment to innovation and long-term growth in the sector[19] - The injection drug ADB116 has received approval to start clinical trials for treating acute ischemic stroke, marking significant progress in the company's human protein drug development[20] Market and Sales Strategy - The increase in revenue was primarily driven by a ¥28,864,200 increase in HIV drug business income and the consolidation of Nanda Pharmaceutical's data for three months compared to one month in the previous year[4] - The company has established a commercial operation system for HIV new drugs, focusing on "medical guidance, market pull, and sales implementation" as its core marketing strategy[14] - The company has optimized market promotion strategies based on clinical research data and real-world study results to support the commercialization process[14] - The company conducted diverse activities in key provinces to enhance awareness of the metabolic advantages of its HIV drug, particularly focusing on weight and blood lipid issues[14] - The company is committed to a differentiated sales model to ensure effective release of commercial value[14] Financial Position - Total assets at the end of the reporting period were ¥1,844,943,110.70, a decrease of 1.32% from the previous year[5] - The company's total assets decreased from ¥1,869.6 million in 2024 to ¥1,844.9 million in 2025, a decline of 1.3%[27] - Total liabilities decreased from ¥802.5 million in 2024 to ¥763.0 million in 2025, a reduction of 4.9%[27] - The company's total current assets amounted to approximately RMB 895.79 million, showing a slight increase from RMB 894.93 million at the end of 2024[25] - The company's cash and cash equivalents stood at approximately RMB 341.02 million, reflecting a stable liquidity position compared to RMB 335.34 million at the end of 2024[25] - The company's cash and cash equivalents increased, contributing to improved liquidity and financial stability[30] - The total equity attributable to shareholders decreased slightly from ¥980.9 million in 2024 to ¥978.0 million in 2025, indicating a stable equity position despite operational challenges[27] Cash Flow - In the first three quarters of 2025, the cash inflow from operating activities reached ¥622,963,170.44, a significant increase of 58% compared to ¥394,442,257.42 in the same period of 2024[32] - The net cash flow from operating activities was ¥27,488,827.13, recovering from a loss of ¥927,675.73 in the previous year[33] - Total cash outflow from operating activities was ¥595,474,343.31, up from ¥395,369,933.15 in the prior year, indicating increased operational expenditures[33] - Cash inflow from investment activities totaled ¥315,741,499.87, down 54% from ¥685,229,113.92 in the same period last year[33] - The net cash flow from investment activities was ¥5,546,049.83, a decrease of 89% compared to ¥51,924,796.07 in 2024[33] - Cash inflow from financing activities was ¥371,924,000.00, an increase of 7% from ¥348,968,000.00 in the previous year[33] - The net cash flow from financing activities showed a decline to -¥20,227,793.53 from a positive ¥55,183,664.22 in the same period last year[33] - The ending balance of cash and cash equivalents was ¥337,018,912.63, slightly up from ¥327,907,012.16 in the previous year[33] - The company reported a significant increase in cash received from other operating activities, which rose to ¥111,673,725.51 from ¥26,250,012.03 in the prior year[32] - The total cash outflow for investment activities was ¥310,195,450.04, down from ¥633,304,317.85 in the same period last year, reflecting a reduction in capital expenditures[33] Non-Operating Income - Non-operating income included government subsidies amounting to ¥4,349,000, contributing positively to the financial results[7] - The company reported a decrease in credit impairment losses and asset impairment losses by approximately 37.36 million yuan compared to the same period last year[9] - Basic and diluted earnings per share increased due to the rise in net profit attributable to shareholders from the beginning of the year to the end of the reporting period[9] International Expansion - The registration certificate for the drug Anomi-T has been granted in Zanzibar, allowing for commercial sales and marking a step forward in international market expansion[23] - The company has actively participated in international academic conferences, enhancing its influence in the global HIV field and showcasing its research capabilities[22]

重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 苏州泽璟生物制药股份有限公司 2025 年第三季度报告 证券代码：688266 证券简称：泽璟制药 苏州泽璟生物制药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 217,789,855.47 | 51.85 | 593,440,129.02 | 54.49 | | 利润总额 | -20,904,645.94 | 不适用 | -9 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥254,545,508.65, a decrease of 35.63% compared to the same period last year[3] - The total profit for the period was ¥3,424,392.71, reflecting a 3.07% increase year-on-year[3] - The net profit attributable to shareholders was a loss of ¥6,802,309.38, with a year-to-date loss of ¥16,794,068.35[3] - The basic earnings per share for the period was -¥0.05, reflecting a decrease in the company's profitability[4] - The net profit for the first three quarters of 2025 was a loss of CNY 13,413,091.39, compared to a profit of CNY 7,816,210.44 in the same period of 2024[18] - The company reported a basic and diluted earnings per share of CNY -0.13 for the first three quarters of 2025, compared to CNY 0.05 in 2024[19] - The total comprehensive income for the first three quarters of 2025 was CNY -12,877,284.84, compared to CNY 7,816,210.44 in 2024, indicating a significant decline[19] Cash Flow - The net cash flow from operating activities for Q3 was -¥20,555,279.65, a decrease of 67.21% compared to the previous year[3] - The company reported a net cash flow from operating activities increase of 96.28% year-to-date, attributed to higher cash receipts from sales[9] - The company reported a significant increase in cash flow from operating activities, totaling CNY 1,138,556,812.64 in the first three quarters of 2025, compared to CNY 878,559,992.67 in 2024, representing a growth of approximately 29.6%[20] - The net cash flow from operating activities was -$6,050,380.47, an improvement from -$162,773,293.79 in the previous period[22] - The company reported a total cash inflow from operating activities of $1,169,202,640.77, an increase from $913,725,388.05[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,806,309,900.09, a decrease of 9.24% from the end of the previous year[4] - The total assets of the company are ¥2,806,309,900.09, down from ¥3,091,938,697.12[15] - Current liabilities total ¥1,512,056,281.17, a decrease from ¥1,757,969,000.47[15] - The total liabilities decreased from CNY 1,939,980,763.08 in 2024 to CNY 1,672,221,898.14 in 2025, a reduction of approximately 13.8%[16] - The total equity attributable to shareholders decreased from CNY 1,144,201,316.47 in 2024 to CNY 1,122,731,403.54 in 2025, reflecting a decline of about 1.9%[16] Research and Development - Research and development expenses totaled ¥8,756,370.38, down 36.74% year-on-year, representing 3.44% of operating revenue[4] - Research and development expenses for the first three quarters of 2025 were CNY 28,805,638.56, down from CNY 36,309,045.77 in 2024, indicating a decrease of about 20.6%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 3,693[11] - The largest shareholder, Yang Ming, holds 59,385,600 shares, representing 45.10% of total shares[12] Inventory and Receivables - Accounts receivable decreased to ¥1,132,402,594.22 from ¥1,395,447,964.13, indicating a reduction of approximately 18.9%[14] - The company reported a decrease in inventory from ¥73,961,590.85 to ¥53,919,004.32, a reduction of approximately 27.1%[14] Other Financial Metrics - The weighted average return on net assets was -0.60%, indicating a decline in profitability[4] - The company experienced a significant decline in gross profit margin due to increased competition and rising fixed asset depreciation costs[8] - The company's other income decreased from CNY 3,026,780.14 in 2024 to CNY 502,503.11 in 2025, a drop of approximately 83.4%[18] Investment Activities - Total cash inflow from investment activities was $97,116,278.54, compared to $73,303,379.60 last year[22] - Cash outflow for investing activities was $115,762,837.56, up from $104,752,423.03 last year[22] - The cash inflow from recovering investments was $95,600,000.00, compared to $73,000,000.00 in the previous period[22] Financing Activities - The net cash flow from financing activities was $53,562,822.34, down from $129,276,145.99 in the previous year[23] - The company received $181,995,152.46 in cash from borrowings, compared to $200,000,000.00 in the previous period[23] - The company paid $14,609,407.12 in dividends and interest, down from $17,573,180.96 last year[23]

浙江康隆达特种防护科技股份有限公司 2025 年第三季度报告 证券代码：603665 证券简称：康隆达 浙江康隆达特种防护科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 2 / 12 （一） 主要会计数据和财务指标 1 / 12 单位：元 币种：人民币 项目 本报告期 本报告期比上 年同期增减变 动幅度(%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 342,701,878.24 15.15 1,056,169,528.58 7.11 利润总额 18,338,094.77 不适用 140,112,447.72 不适用 归属于上市公司股东的 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥250,413,670.56, representing a year-on-year increase of 30.10%[4] - The total profit for the period was ¥40,426,547.89, while the net profit attributable to shareholders was ¥37,592,835.95[4] - The basic earnings per share for the quarter was ¥0.15, unchanged from the previous period[4] - The net profit for the first three quarters of 2025 is CNY 43,746,733.78, a significant recovery from a net loss of CNY 9,848,210.69 in the same period of 2024, indicating a turnaround in performance[20] - Operating profit for the first three quarters of 2025 is CNY 48,653,794.88, compared to an operating loss of CNY 19,226,905.78 in the previous year, reflecting improved operational efficiency[20] - The total profit for the first three quarters of 2025 is CNY 48,050,335.87, compared to a total loss of CNY -18,907,897.85 in the same period of 2024, indicating a significant improvement[20] - The basic and diluted earnings per share for the first three quarters of 2025 are both CNY 0.19, a recovery from a loss of CNY -0.01 per share in the same period of 2024[21] Assets and Liabilities - Total assets decreased by 8.77% compared to the end of the previous year, amounting to ¥4,225,908,782.17[5] - Current assets totaled ¥2,100,970,541.70 as of September 30, 2025, compared to ¥2,468,570,533.57 at the end of the previous period, reflecting a decrease of approximately 14.9%[14] - Non-current assets amounted to ¥2,124,938,240.47, down from ¥2,163,379,445.56, indicating a decline of about 1.8%[15] - Total assets decreased to ¥4,225,908,782.17 from ¥4,631,949,979.13, representing a reduction of approximately 8.8%[16] - Total liabilities were reported at ¥2,564,572,740.76, down from ¥3,014,098,063.50, reflecting a decrease of about 15%[16] - Shareholders' equity totaled ¥1,661,336,041.41, slightly up from ¥1,617,851,915.63, indicating an increase of approximately 2.7%[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥1,266,057.18, indicating a significant cash outflow[4] - The company reported a net cash outflow from operating activities of CNY -1,266,057.18 for the first three quarters of 2025, compared to a larger outflow of CNY -101,479,328.92 in the same period of 2024[24] - Cash and cash equivalents at the end of the third quarter of 2025 stand at CNY 227,877,982.94, down from CNY 432,872,902.24 at the end of the same period in 2024, indicating a decrease of approximately 47.4%[25] Operating Costs and Expenses - Total operating costs decreased to ¥627,988,089.59 in the first three quarters of 2025, down from ¥669,647,614.70 in 2024, indicating a reduction of about 6.2%[19] - Operating costs included ¥451,930,638.74 for the first three quarters of 2025, slightly up from ¥448,717,728.60 in 2024, showing a marginal increase of 0.5%[19] - The company incurred financial expenses of CNY 50,816,862.11 in the first three quarters of 2025, a decrease from CNY 59,117,403.59 in the same period of 2024, representing a reduction of approximately 14.5%[20] - Research and development expenses for the first three quarters of 2025 are CNY 22,099,669.22, down from CNY 35,220,031.72 in the same period of 2024, reflecting a reduction of about 37.2%[20] Shareholder Information - The company’s equity attributable to shareholders increased by 3.12% year-on-year, totaling ¥1,563,402,541.72[5] - The top shareholder, Changjiang Ecological Environmental Group Co., Ltd., holds 24.73% of the shares[11] Other Information - Non-operating income for the quarter included government subsidies amounting to ¥1,178,087.95[7] - The weighted average return on equity for the quarter was 2.44%[5] - The company reported a decrease in accounts receivable credit impairment losses, contributing to improved profitability[9] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided content[19] - The company has not applied new accounting standards or interpretations for the first time in 2025, indicating continuity in accounting practices[26]

四川水井坊股份有限公司 2025 年第三季度报告 证券代码：600779 证券简称：水井坊 四川水井坊股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人胡庭洲、主管会计工作负责人蒋磊峰及会计机构负责人（会计主管人员）徐金金保证 第三季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 四川水井坊股份有限公司 2025 年第三季度报告 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | ...